Associated tags: ROCK, ICE, Biotechnology, Patient, Cancer, Pharmaceutical industry, Affimer, NK, Vaccine
Locations: HEIDELBERG, SEOUL, CHICAGO, IL, SWITZERLAND, BERLIN, CALIFORNIA, CR, SD, MANNHEIM,, DE, GERMANY
Retrieved on:
Wednesday, April 24, 2024
MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE®), in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Key Points:
- MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE®), in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Details of the poster presentation are as follows:
The full abstract will become available on ASCO’s website on May 23, 2024 at 5:00 p.m. (EDT).
- More details about the ASCO conference are available online at Attend | ASCO Annual Meeting .
Research,
EGFR,
GVHD,
NSCLC,
Genentech,
ASH,
AML,
PD,
Disease,
International,
International Financial Reporting Standards,
Patient,
Webcast,
EFS,
EDT,
CRS,
Cancer,
Record,
Insurance,
Trial of the century,
Bank statement,
Investment,
Safety,
Workforce,
Roivant Sciences,
PFS,
IASB,
Hodgkin lymphoma,
Book,
NK,
HL,
Cytokine release syndrome MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
Key Points:
- MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
- Based on the promising results, Affimed expanded enrollment in this cohort to 40 patients.
- Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
- Affimed will host a conference call and webcast on March 28, 2024, at 8:30 a.m. EDT / 13:30 CET to discuss full year 2023 financial results and corporate developments.
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024.
Key Points:
- MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024.
- The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.
- The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
The reverse stock split is expected to be effected after market close on March 8, 2024, with the Common Shares expected to begin trading on the Nasdaq Capital Market (“NASDAQ”) on a post-split basis at market open on March 11, 2024 under the Company’s existing trading symbol “AFMD.”
Key Points:
- The reverse stock split is expected to be effected after market close on March 8, 2024, with the Common Shares expected to begin trading on the Nasdaq Capital Market (“NASDAQ”) on a post-split basis at market open on March 11, 2024 under the Company’s existing trading symbol “AFMD.”
No fractional shares will be issued in connection with the reverse stock split.
- Shareholders that would hold a fractional share as a result of the reverse stock split will receive a cash payment in lieu of such fractional shares.
- The reverse stock split was approved by the Company’s shareholders at the Company’s Annual General Meeting of Shareholders held on June 21, 2023 and is intended to bring the Company into compliance with the minimum $1.00 per share requirement for continued listing on NASDAQ.
- Additional information concerning the reverse stock split can be found in Affimed’s proxy materials filed with the Securities and Exchange Commission (the “SEC”) on May 22, 2023 and June 22, 2023, as well as on Affimed’s Investor Relations website, https://www.affimed.com/investors/ .
Initial data as presented on December 11, 2023, showed 1 confirmed PR as well as 1 unconfirmed CR, and 2 unconfirmed PRs.
Key Points:
- Initial data as presented on December 11, 2023, showed 1 confirmed PR as well as 1 unconfirmed CR, and 2 unconfirmed PRs.
- Based on the promising response data from the EGFRwt NSCLC cohort, Affimed will expand enrollment to 40 patients.
- Additionally, the Company reported that enrollment of the EGFRmut NSCLC cohort is ongoing.
- “There is a significant unmet need for these patients who have exhausted all previous lines of therapy and did not respond to any therapies, including PD-1/PD-L1 treatment.
Workforce,
Lung cancer,
Research,
CMO,
EGFR,
Merck Serono,
Therapy,
Cancer,
Head,
Management,
Supervisory board,
Patient,
Clinical Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
Key Points:
- Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
- "On behalf of Affimed, I would like to thank Adi for his dedication to the Company.
- "On behalf of Affimed, I wish Adi all the best in his future endeavors."
- Key highlights of the restructuring plan include:
Focus on Clinical Programs: Affimed will direct all resources towards advancing the development of its clinical programs.
Retrieved on:
Wednesday, January 3, 2024
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
Key Points:
- MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
- Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 million in cash to be paid in two tranches, and $1 million in Ampersand common stock, subject to certain adjustments and a holdback.
- Affimed is also entitled to receive milestone payments from a pre-existing AbCheck partnership.
Retrieved on:
Monday, December 11, 2023
Stomach,
EST,
Hepatocellular carcinoma,
RECIST,
EGFR,
Progression-free survival,
Cancer,
Pancreatic cancer,
Toxicity,
Cholangiocarcinoma,
Webcast,
Patient,
Safety,
NSCLC,
Pharmaceutical industry The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.
Key Points:
- The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.
- The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 unconfirmed CR, 3 PRs (1 confirmed, 2 unconfirmed) and 7 patients exhibiting SD.
- Considering the low ORR reported on atezolizumab monotherapy in checkpoint inhibitor-relapsing and refractory patients, Affimed believes the clinical activity observed in AFM24-102 is likely due to the synergy of AFM24 with atezolizumab.
- AFM24 has demonstrated a positive safety and tolerability profile as both a monotherapy and in combination therapy.
Retrieved on:
Monday, December 11, 2023
Patient,
EST,
Haematopoietic system,
Dor,
EFS,
MD Anderson Cancer Center,
Graft-versus-host disease,
Society,
Cancer,
ASH,
HL,
CRS,
PST,
Webcast,
Safety,
University,
BV,
Pharmaceutical industry Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
Key Points:
- Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
- A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
- 32 of the 36 patients treated at the RP2D were HL patients.
- For the HL patients treated at the RP2D, median EFS was 9.8 months - with 84% patients alive at 12 months.
During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
Key Points:
- During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
- The conference call will be available via phone and webcast.
- The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
